ARS Pharma Advances EURneffy Nasal Spray Portfolio With Pediatric Indication

ARS Pharmaceuticals announced a major regulatory milestone as the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion supporting an expanded marketing authorization. The backing reinforces the company’s strategy to broaden its nasal spray product line across different patient populations. The newly supported indication targets children weighing between 15 kg and less than 30 kg who face emergency scenarios involving allergic reactions from insect stings or bites, foods, or medications, as well as idiopathic or exercise-induced anaphylaxis cases.

CHMP Support Expands Treatment Access for Pediatric Patients

The regulatory endorsement builds on previous approvals of EURneffy 2 mg, which received European Commission clearance in August 2024 for emergency treatment of anaphylaxis in adults and children weighing 30 kg or more. This progression demonstrates how the nasal spray formulation is being systematically adapted to serve different age and weight segments. The lower-dose formulation designed for lighter children addresses a critical gap in accessible emergency treatment options, particularly given the convenience advantages of nasal administration over traditional injection-based epinephrine delivery. The regulatory differentiation by weight category reflects clinical evidence supporting dose optimization for pediatric safety and efficacy.

Global Expansion Reflects Growing Market Confidence

The approval momentum extends far beyond Europe. EURneffy is commercially available in the United States under the brand name neffy, already serving patients requiring emergency allergic reaction management. Throughout 2025, the product has been deployed across selected European countries and the United Kingdom, with recent approvals obtained in Japan, China, and Australia. The market expansion pipeline continues to advance, with Canadian regulatory approval anticipated during the first half of 2026. This staggered global rollout positions ARS Pharma to capture market opportunities across major pharmaceutical markets.

Market Response Signals Investor Optimism

ARS Pharma shares reflected the positive regulatory development with gains in premarket trading, demonstrating investor confidence in the company’s ability to expand its addressable patient population. The sequential approval approach—first the 2 mg formulation, then the pediatric 1 mg indication—showcases a disciplined commercialization strategy. As healthcare systems increasingly recognize the value of accessible, user-friendly emergency treatment tools, the expanded nasal spray portfolio positions the company at the forefront of innovation in anaphylaxis management.